Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis Positions Neurizon to advance the ...
“The European Medicines Agency might supplant the FDA as the gold standard if the FDA goes off track and is politically ...
The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ... Read ...
About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...
Modern pharmaceuticals have revolutionised disease prevention and treatment. But eventually, the chemicals can end up in rivers, oceans and soils.
The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...